# Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00054119** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 27 (actual)

## Conditions studied

- Primary Peritoneal Carcinoma
- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Cositecan
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT00054119
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2005-09-30
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054119, "Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00054119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*